Rise Therapeutics Secures New Funding to Advance First-in-Class R-2487 Oral Immune Biomodulator into Sjogren's Disease Clinical Testing ...Middle East

Supported by recent clinical data from the first-ever clinical study of an oral dendritic cell (DC) modulator in rheumatoid arthritis (RA), Rise Therapeutics is expanding into a second autoimmune indication, Sjögren's Disease (SjD) ROCKVILLE, Md., Sept. 23, 2025 /PRNewswire/ -- Rise...

Hence then, the article about rise therapeutics secures new funding to advance first in class r 2487 oral immune biomodulator into sjogren s disease clinical testing was published today ( Tuesday 23/09/2025 - 04:12 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Rise Therapeutics Secures New Funding to Advance First-in-Class R-2487 Oral Immune Biomodulator into Sjogren's Disease Clinical Testing )

Also on site :

• ‘Bridgerton’ Star Yerin Ha Reveals the One Prop She Couldn’t Resist Taking Home (Exclusive)
• Trump administration charges 30 more people for Minnesota church protest
• Carole King Pays Tribute to High School Sweetheart Neil Sedaka